Sunshine Act transparency rule extended

The Centers for Medicare & Medicaid Services (CMS) last week finally proposed a Sunshine Act transparency rule, in which drug and device manufacturers must disclose information about their relationships with teaching hospitals and physicians, FierceHealthcare reports. The Sunshine rule, effectively proposed to start by March 31, 2013, requires manufacturers of drugs, devices, biologicals and medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program to report CMS payments or other transfers of value they make to physicians and teaching hospitals. It also requires manufacturers and group-purchasing organizations to disclose to CMS physician ownership or investment interests. --Read the full report from FierceHealthcare